Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.5K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.5K
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

277
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
277
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

33.0K
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
33.0K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

406
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
406
Liver Physiology01:30

Liver Physiology

2.6K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
2.6K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

49
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
49

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Transitional Liver Clinic: Study protocol for a stepped-wedge cluster randomized trial.

Hepatology communications·2026
Same author

Myeloid HDAC7 drives liver inflammation and systemic glucose dysregulation during diet-induced obesity.

Clinical & translational immunology·2026
Same author

Ascites Bactericidal Capacity in Patients With Decompensated Cirrhosis.

Cellular and molecular gastroenterology and hepatology·2026
Same author

Spleen Size may Also be an Important Prognostic Indicator of Liver-Related Outcomes in Metabolic-Dysfunction-Associated Steatotic Liver Disease Patients Without Clinically Significant Portal Hypertension.

Journal of clinical and experimental hepatology·2026
Same author

Progressive fibrosis in human MASLD is associated with spatially linked transcriptomic signatures of metabolic reprogramming and senescence.

JHEP reports : innovation in hepatology·2026
Same author

MASLD fibrosis stage F3 is morphologically and transcriptomically diverse: Implications for assessing therapeutic response.

Journal of hepatology·2025

Related Experiment Video

Updated: Nov 8, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.2K

Non-alcoholic fatty liver disease.

Elizabeth E Powell1, Vincent Wai-Sun Wong2, Mary Rinella3

  • 1Centre for Liver Disease Research, Faculty of Medicine, University of Queensland, Translational Research Institute, Brisbane, QLD, Australia; Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, QLD, Australia.

Lancet (London, England)
|April 24, 2021
PubMed
Summary

Non-alcoholic fatty liver disease (NAFLD) affects 25% globally, progressing to cirrhosis and liver cancer. Lifestyle changes and weight reduction are key for prevention and treatment, as effective therapies are still developing.

More Related Videos

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.4K
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

7.0K

Related Experiment Videos

Last Updated: Nov 8, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.2K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.4K
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

7.0K

Area of Science:

  • Hepatology
  • Metabolic Diseases
  • Public Health

Background:

  • Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global population.
  • NAFLD is a spectrum, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), characterized by inflammation and fibrosis.
  • NAFLD is closely linked with metabolic syndrome and type 2 diabetes, increasing risks for liver complications.

Purpose of the Study:

  • To summarize the current understanding of NAFLD.
  • To highlight the prognostic significance of liver fibrosis in NAFLD.
  • To discuss current and future therapeutic strategies for NAFLD.

Main Methods:

  • Literature review of NAFLD prevalence, pathophysiology, and clinical outcomes.
  • Analysis of the association between NAFLD and metabolic syndrome components.
  • Review of diagnostic approaches for advanced liver fibrosis.
  • Examination of current and emerging treatment options for NAFLD.

Main Results:

  • NAFLD is a prevalent condition with significant associations with metabolic syndrome and type 2 diabetes.
  • Advanced liver fibrosis is a critical predictor of liver-related mortality and overall survival in NAFLD patients.
  • Non-invasive tests can effectively assess liver fibrosis.
  • No approved therapies currently exist, but combination treatments are anticipated due to disease heterogeneity.

Conclusions:

  • NAFLD poses a major global health challenge, linked to serious liver conditions like cirrhosis and cancer.
  • Early detection and management of fibrosis are crucial for improving patient outcomes.
  • Lifestyle modifications, including weight reduction, are fundamental for NAFLD management.
  • Future treatments will likely involve combination therapies tailored to individual patient needs.